Clinical Trial Update: Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating an allogeneic engineered hematopoietic stem cell transplant lacking CD33, with post-transplant Mylotarg, in CD33-positive ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Allogeneic engineered hematopoietic stem cell transplant lacking CD33 protein
• Mylotarg (gemtuzumab ozogamicin)

Snippet

Sponsor: Vor Biopharma | Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: TERMINATED